NovaBay Pharmaceuticals to Distribute the NuLids System® for the Treatment of Dry Eye in Certain U.S. Geographies
28 October 2019 - 9:50PM
Business Wire
Once-daily system complements Avenova and
leverages salesforce calls on eyecare specialists
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing Avenova® for
the domestic eye care market, announces an exclusive 90-day
agreement with NuSight Medical® to distribute the NuLids System for
treatment of blepharitis and dry eye in six of NovaBay’s
top-performing territories. The NuLids System is a hand-held,
cordless device that safely and effectively removes accumulated
scurf from eyelashes and eyelids, while stimulating meibomian gland
production in dry eye and blepharitis patients. The NuLids System
is available through eyecare professionals for home use by the
patient.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191028005179/en/
NuLids System® for the Treatment of Dry
Eye (Photo: Business Wire)
“The NuLids System is highly complementary to Avenova and, in
fact, we believe that anyone using this product should also be
using Avenova to treat both the symptoms and the underlying cause
of blepharitis and bacterial dry eye,” said Justin Hall, NovaBay
CEO. “We further believe the NuLids System will elevate our sales
calls with ophthalmologists and optometrists and make our
salespeople more productive. The NuLids System is available through
eyecare professionals, which supports our buy-and-sell sales
channel for Avenova. We expect to begin selling the NuLids System
at the beginning of November in the greater mid-Atlantic
region.”
“We are delighted to be working with NovaBay, which has a
salesforce that is dedicated to the treatment of dry eye and has
established relationships with eyecare specialists,” said Robert
Foster, NuSight Medical CEO. This agreement expands upon our
existing professional dealer network with a highly credible
distribution partner in a large geographic territory that had
previously been underserved. This agreement represents an exciting
opportunity to serve dry eye sufferers and their eye care
professionals, who may be currently unaware of the NuLids System’s
exceptional results in ending or substantially reducing that
scratchy, gritty, itching, burning and/or sandy feeling in the eye.
One-year patient survey data has shown that 96% of patients
surveyed after a 30-day trial reported being either ‘satisfied’ or
‘very satisfied’ with NuLids.”
The NuLids System is easy to use and requires just one minute
each day to treat both eyes. Clinical results show a significant
reduction in the signs and symptoms associated with dry eye, e.g.,
an improvement in the number of glands secreting important oils,
called meibum, of 81%. These oils are necessary for good tear film
quality, comfort and health.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
About NuSight Medical®: Comfort in the Blink of an
Eye
Teeny Clean, LLC, dba NuSight Medical, is a medical device
company focusing on commercializing and developing its NuLids
System® for more effective treatment of Dry Eye Disease and
its many related conditions. The NuLids System is the unique,
patented, mechanical device that is directed by eye care
practitioners for the home-based treatment of Dry Eye Disease and
Blepharitis. These markets exceed 400 million people globally.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding potential partnerships, future
collaborations, the impact of new products on our business, and
generally the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, improving sales rep productivity and
product distribution, and any potential regulatory problems. Other
risks relating to NovaBay’s business, including risks that could
cause results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay’s latest Form 10-Q/K filings with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow us
on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191028005179/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024